Vertex Pharmaceuticals (VRTX) Total Current Liabilities (2009 - 2026)

Vertex Pharmaceuticals' Total Current Liabilities history runs 18 years deep, the most recent figure standing at $3.9 billion for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 2.57% year-over-year to $3.9 billion; the TTM figure through Mar 2026 stood at $3.9 billion (up 2.57% YoY), while the FY2025 annual figure was $3.9 billion, up 8.32% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $3.9 billion, up from $3.9 billion in the prior quarter.
• The five-year high for Total Current Liabilities was $4.5 billion in Q3 2025, with the low at $2.2 billion in Q1 2022.
• The 5-year median for Total Current Liabilities is $3.6 billion (2024), against an average of $3.4 billion.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities surged 39.19% in 2022, then slipped 0.33% in 2025.
• Vertex Pharmaceuticals' Total Current Liabilities stood at $2.7 billion in 2022, then grew by 29.37% to $3.5 billion in 2023, then grew by 0.48% to $3.6 billion in 2024, then climbed by 8.32% to $3.9 billion in 2025, then gained by 0.5% to $3.9 billion in 2026.
• Business Quant data shows VRTX's Total Current Liabilities at $3.9 billion in Q1 2026, $3.9 billion in Q4 2025, and $4.5 billion in Q3 2025.